Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00341341 · ClinicalTrials.gov registry record

Impact of Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk and Receptivity to Quit Smoking

A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).

Completed
Registry status
757
Enrollment target

NCT00341341: Completed study, sponsored by National Human Genome Research Institute (NHGRI).

NCT00341341 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 757 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00341341 has completed, sponsored by National Human Genome Research Institute (NHGRI).

COMPLETED
Registry status
757 participants
Enrollment target

Study Summary

This study will explore beliefs and knowledge about genetics and smoking among smokers who have a first or second degree relative with advanced lung cancer, and whether their understanding of genetic risk influences their desire to quit smoking. Healthy adult smokers between 18 and 55 years of age who are first or second degree relatives (e.g., siblings, children, grandchildren, nieces, nephews, grandnieces or grandnephews) of a patient with advanced lung cancer who is receiving care at the Moffitt Cancer Center and Research Institute in Tampa, Fla. and the GUMC/LCCC, may be eligible for this study. Participants must be able to complete computer online surveys. Participants log on to a password-protected website to complete online educational sessions and surveys. The educational sessions include information on: 1) the role of smoking and genetics in the development of lung cancer; 2) glutathione S transferase (GSTM1), an enzyme made by the GSTM1 gene that "cleans up" toxins such as cigarette smoke and that may play a role in preventing lung cancer from developing; 3) pros and cons of being tested for GSTM1; and 5) a series of questions and answers about genetic testing. Participants are offered free genetic testing for GSTM1, and those who wish to be tested are sent materials to collect a sample from inside the cheek using a mouth rinse and return it to a laboratory at Duke University Medical Center. They later receive their results online. Participants also complete online surveys that ask about their risk perceptions, beliefs and attitudes related to lung cancer, emotional responses to their relative's diagnosis, smoking history and motivation to quit, reactions to information about smoking and genetic risk, and interest in receiving smoking cessation services. They are asked to review depictions and descriptions of smoking cessation materials offered through a quit smoking program at Duke University Medical Center and to evaluate the extent to which the vario

Trial Details

FieldValue
Enrollment Target 757 participants
Start Date 2004-12-07
Est. Completion 2010-07-16

What the finished NCT00341341 record still lists

NCT00341341 is an observational study that tracks outcomes without assigning an intervention. The registered 757 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00341341 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00341341 about?

NCT00341341 is a clinical study titled "Impact of Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk and Receptivity to Quit Smoking". This study will explore beliefs and knowledge about genetics and smoking among smokers who have a first or second degree relative with advanced lung cancer, and whether their understanding of genetic risk influences their desire to quit smoking. Healthy adult smokers between 18 and 55 years of age ...

What is the current status of trial NCT00341341?

This trial is currently completed. The enrollment target is 757 participants. The study started on 2004-12-07. Estimated completion is 2010-07-16.

Who is sponsoring clinical trial NCT00341341?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05869149 · 756 participants · NA

    Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial

  • NCT06095583 · 756 participants · Phase 3

    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

  • NCT02089607 · 760 participants · NA

    CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft

  • NCT04073706 · 760 participants · Phase 3

    Sentinel Node Biopsy in Endometrial Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00341341, the US trial registry maintained by the National Library of Medicine. NCT00341341 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.